Background
Methods
Search strategy
Inclusion and exclusion criteria
Results
Authors & Years | Type of Study | Patients (total) | Patients (Salpingectomy) | Patients-Controls | Age (year ± SD) | BMI (± SD) | Indication for Surgery | Time from Surgery | Reason of Infertility | Duration of Infertility |
---|---|---|---|---|---|---|---|---|---|---|
Lass et al. [1] | OP | 102 | a) 29 SLP (ECP) Type: unilateral Surgery: not specified | b) 73 no surgery (healthy subjects) | a) 33.1 ± 4.9 b) 34.2 ± 4.1 |
n.r
| a) ECP | 2 years | a,b) MF 31; ID 42 | 2 years after surgery at least |
Dechaud et al. [2] | RCT | 60 | a) 30 SLP (HY) Type: not specified Surgery: LPS | b) 30 diagnostic LPS (TF, HY) | a) 31.7 ± 4.5 b) 30.6 ± 3.3 |
n.r
| a,b) salpingitis or HY | a) 10.1 ± 7.5 months b) 9.5 ± 7.2 months (LPS diagnostic) | a,b) TF | a) 55.2 ± 33.3 months b) 48 ± 25.4 months |
Bredkjaer et al. [3] | R | 278 | a) 139 SLP (HY) Type: 128 bilateral, 11partial Surgery: not specified | b) 139 no surgery (TF, no HY) | a) 32.6 (22–39) b) 32.9 (24–40) |
n.r
| a) HY | 92 pz between 1.5 and 5 years 47 pz 3–6 months | a,b) TF | n.r |
Strandell et al. [4] | RCT | 204 | a) 116 SLP (HY) Type: not specified Surgery: LPS | b) 88 no surgery (TF, HY) | a) 31.8 ± 3.6 b) 31.8 ± 3.7 |
n.r
| a,b) HY uni o bilateral | 2 months (at least) | a,b) TF | 1 month to 2 years |
Dar et al. [5] | R | 26 | a) 26 SLP (ECP) Type : 25 unilateral, 1 bilateral Surgery: LPS | Control: same patients before surgery | a) 31.7 ± 3.6 |
n.r
| a) ECP | a period < 3 years between the cycles (before and after surgery) | a) MEF 16; MF 6 AN 1; END 1; ID 2 | n.r |
Strandell et al. [6] | OP | 26 | a) 26 SLP (HY) Type: 9 unilateral and 17 bilateral Surgery: LPS | Control: same patients before surgery | a) 32.7 ± 3.6 |
n.r
| a) HY | n.r |
n.r
| n.r |
Strandell et al. [7] | RCT | 185 | a) 103 SLP (HY) Type: 40 unilateral, 63 bilateral Surgery: LPS | b) 82 no surgery (TF, HY) | a) 32.8 ± 3.5 b) 32.5 ± 3.8 |
n.r
| a) HY | n.r | a,b) TF | n.r |
Surrey et al. [8] | R | 94 | a) 32 SLP (HY) Type: not specified Surgery: LPS | b) 15 PTO (HY) c) 35 no surgery (TF no HY) d) 12 tubal ligation (prior sterilization) | a) 35.1 ± 0.7 b) 35.4 ± 1.0 c) 35.6 ± 0.7 d) 38.2 ± 1.0 |
n.r
| a,b) HY c,d) TF | 6 months | a,b,c,d) TF | n.r |
Tal et al. [12] | OP | 78 | a) 26 SLP (ECP) Type: unilateral Surgery: 14 LPT, 12 LPS | b) 52 no surgery (healthy subjects) | a) 32.1 ± 4.1 b) 32.0 ± 5.1 |
n.r
| a) ECP | 1-9 years |
n.r
| n.r |
Chan et al. [13] | R | 32 | 32 SLP (ECP) a) 18 unilateral LPS b) 14 unilateral LPT | Controls: non-operated site | a) 34 (31–38) b) 36 (33–44) | a) 20.96 b) 21.44 | a,b) ECP | 3 months (at least) |
n.r
| n.r |
Kontoravdis et al. [9] | RCT | 115 | a) 50 POT (HY) b) 50 SLP (HY) Type: not specified Surgery: LPS | c) 15 no surgery (HY) | a) 31 ± 4.5 b) 29.8 ± 3.4 c) 34 ± 5.3 |
n.r
| a,b) HY unilateral or bilateral | n.r |
n.r
| n.r |
Gelbaya et al. [6] | R | 168 | a) 40 SLP (HY) Type: 16 unilateral, 24 bilateral b) 25 PTD Type: 9 unilateral, 16 bilateral Surgery: LPS | c) 103 no surgery (tubal factor, no HY) | a) 32.8 ± 3.57 b) 33.1 ± 2.71 c) 33.5 ± 3.32 |
n.r
| a,b) HY | 3 months at least |
All TF plus:
a) MF 2/40; OF 4/40; END 2/40 b) MF 5/25;OF 5/25; END 1/25 c) MF 12/103; OF 9/103; END 5/103 | n.r |
Moshin & Hotineanu [11] | RCT | 204 | a) 60 SLP (HY) b) 78 PTO (HY) Type: not specified Surgery: not specified | c) 66 no surgery (HY) | n.r |
n.r
| a,b) HY | n.r |
n.r
| n.r |
Sezik et al. [16] | RCT | 24 | a) 12 total hysterectomy + bilateral- SLP Surgery: LPT | b) 12 total hysterectomy without SLP | a) 41.6 ± 1.7 b) 41.1 ± 1.4 | a) 24.5 ± 2.2 b) 26.6 ± 4.8 | n.r | n.r |
n.r
| n.r |
Nakagawa et al. [17] | P | 17 | a) 6 SLP (HY) Type: not specified Surgery: LPS | b) 11 PTD (HY) | a) 31.7 ± 6.3 b) 35.3 ± 3.6 |
n.r
| a,b) HY | n.r |
n.r
| n.r |
Orvieto et al. [18] | R | 15 | a) 15 SLP (HY) Type: not specified Surgery: not specified | Controls: same patients before surgery | a) 32 ± 4.4 | 24 ± 5.5 | a) HY | n.r |
n.r
| n.r |
Almog et al. [19] | R | 36 | a) 36 SLP Type :22 unilateral, 14 bilateral Surgery: LPS | Controls: same patients before surgery | a) 34.2 ± 4.5 |
n.r
| a) ECP 21 HY 14 Both 1 | 152 ± 36 days |
n.r
| n.r |
Xi et al. [20] | R | 156 | a) 76 SLP (ECP) Type: 32 bilateral, 44 unilateral (23 controlateral ligation) Surgery: LPS | Controls: same patients before surgery b) 80 no surgery (healthy subjects) | a) 31.5 ± 4.2 |
n.r
| a) ECP | At least 3 months after salpingectomy | a) TF 54 MF 7 END 5 | n.r |
Na et al. [21] | R | 97 | a) 41 SLP (HY) Type: not specified Surgery: LPS | b) 56 sclerotherapy (HY) | a) 32.4 ± 4.5 b) 32.9 ± 4.1 | a) 22.2 ± 5.0 b) 21.5 ± 2.2 | a, b) HY | n.r | a,b) HY | a) 3.8 ± 3.4 b) 2.9 ± 1.8 |
Ni et al.[22] | PC | 134 | 60 SLP a) 26 bilateral b) 34 unilateral c) 23 PTO Surgery: LPS | d) 51 no surgery (TF, no HY) | a) 29.23 ± 2.98 b) 30.12 ± 3.73 c) 30.65 ± 3.32 d) 29.18 ± 3.36 | a) 21.21 ± 2.05 b) 21.37 ± 1.89 c) 20.78 ± 2.04 d) 20.95 ± 1.66 | a, b) ECP, HY c) HY | n.r | TF n.s | a) 2.00 ± 1.67 years b) 3.14 ± 2.12 c) 4.61 ± 2.81 d) 3.98 ± 2.44 |
Uyar et al. [23] | OP | 162 | a) 33 patients (ECP) - 26 unilateral SLP - 3 salpingostomy - 1 tubal milkink - 1 fimbriectomy - 2 tubal abortion surgery: LPS/LPT | b) 49 MTX (ECP) c) 80 no surgery | a) 31.1 ± 5.1 b) 29.7 ± 5.0 c) 28.9 ± 6.0 |
n.r
| a, b) ECP | n.r |
n.r
| n.r |
Lin et al. [24] | R | 288 cycles in 251 women | a) 103 cycles in 96 SLP Type: not specified Surgery: LPS | b) 185 cycles in 155 women (prior sterilization, tuboplasty, PTO) TF infertility | a) 33.2 ± 4.2 b) 32.8 ± 4.6 | a) 22.1 ± 4.3 b) 21.9 ± 3.2 | a) ECP or HY | n.a | a,b) TF | n.a |
Grynnerup et al. [25] | P-CS | 71 | a) 16 SLP (HY) Type: (uni/ bilateral) not specified Surgery: LPS | b) 42 no surgery (TF, with or without HY) c) 13 no surgery (unexplained infertility, no HY) | a) 34 (25–37) b) 33 (26–37) c) 32 (27–36) |
n.r
| a) HY | At least 2 months | a) HY 16 b) TF 42 c) ID 13 | a) 5 years b) 4 years c) 5 years |
Findley et al. [26] | RCT | 30 | a) 15 hysterectomy + bilateral SLP Surgery: LPS | b) 15 hysterectomy with no SLP LPS | a) 36.6 ± 4.5 b) 37.8 ± 5.0 | a) 34.4 ± 6.8 b) 38.1 ± 10.7 | a,b) benign indications | n.r |
n.r
| n.r |
Hill et al. [27] | R | 189 | a) 36 SLP (ECP) Type: unilateral Surgery: not specified | Controls: same patients before surgery b) 153 MTX (ECP) | a) 35.8 ± 4.3 b) 34.3 ± 4.5 |
n.r
| a,b) ECP | n.r |
n.r
| n.r |
Ye et al. [28] | R | 198 | 124 SLP (HY, ECP, TOA) a) 83 unilateral b) 41 bilateral Surgery: not specified | c) 74 no surgery (infertility, no TF) | a) 33,02 ± 4,66 b) 33,58 ± 3,95 c) 33,8 ± 4,67 | a) 21,63 ± 2,46 b) 21,1 ± 2,85 c) 21,43 ± 2,83 | a) ECP 79 HY 3 TOA 1 b) ECP 24 HY 16 TOA 1 | n.r | a) MF 45; MF & FF 28 b) MF 16 MF & FF 15 c) MF 38 MF & FF 26 UNKNOWN 2 | a) 0.31 ± 1.13 PI 2.85 ± 2.81 SI b) 0.82 ± 1.96 PI 3.23 ± 3.24 SI c) 3.6 ± 4.15 PI 2.36 ± 3.32 SI |
Pereira et al. [29] | R | 144 | a) 37 SLP (ECP) Type: unilateral Surgery: LPS b) 107 MTX (ECP) | Controls: same patients before surgery or MTX | a) 36.4 ± 3.03 b) 37.1 ± 4.01 | a) 24 ± 3.65 b) 23.2 ± 4.23 | a,b) ECP | 12 months | a) A 31.8 %; TF 3 13.6 %; END 9 %; MF 18.1 %; ID 4.55 %; Other 18.1 % b) AN 32.9 %;TF 12.5 %: END 7.95 %; MF 23.9 % ID 5.68 % Other 15.9 % | n.r |
Odesjo et al. [30] | R | 153 | a) 118 SLP (ECP) Type: unilateral Surgery: not specified | b) 35 unilateral salpingotomy (ECP) | a) 32.5 ± 3.93 b) 33.8 ± 3.07 | a) 24.9 ± 4.5 b) 24 ± 3.76 | a,b) ECP | a) 3.11 ± 2.90 years b) 6.85 ± 5.05 years | a) TF 92 (78 %) a) other reasons 26 (22 %) b) TF 24 (70.6 %) b) other reason 10 (29.4 %) | n.r |
Venturella et al. [31] | RCT | 186 | a) 91 SLP standard b) 95 SLP wide* Type: bilateral surgery: LPS | Controls: same patients before surgery | a) 41.16 ± 5.33 b) 41.56 ± 5.45 |
n.r
| a,b) myomectomy, tubal surgical sterilization | n.a |
n.a
| n.a |
OVARIAN RESERVE | |||||||
---|---|---|---|---|---|---|---|
Authors & Years | Patients | AMH ± SD |
p
| AFC ± SD/range |
p
| FSH ± SD/range |
p
|
Surrey et al. [8] | a) 32 SLP (HY) Type: not specified b) 15 PTO (HY) c) 35 no surgery (TF no HY) d) 12 tubal ligation |
n.r.
|
n.r.
| a) 7.07 ± 0.12 b) 6.65 ± 0.42 c) 7.08 ± 0.23 d) 7.47 ± 0.25 |
ns
| ||
Chan et al. [13] | 32 SLP (ECP) a) 18 unilateral LPS b) 14 unilateral LPT |
n.r
| - |
Operated site
a) 5. 0 (3.0-7.3) b) 6.5 (1.8-10.3)
Non operated site
a) 7.5 (4.8-8.3) b) 4.0 (2.8-9.3) | a) .05
b) ns
|
n.r
| - |
Gelbaya et al. [10] | a) 40 SLP (HY) Type: 16 unilateral, 24 bilateral b) 25 PTD Type: 9 unilateral, 16 bilateral c) 103 no surgery (tubal factor, no HY) |
n.r
|
-
|
n.r
| - |
IU/L
a) 6.8 ± 1.3 pre 7.61 ± 2.31 post b) 6.4 ± 1.5 pre 6.35 ± 1.51 post c) 6.6 ± 2.3 pre 6.71 ± 2.32 post | a) .05
b) ns
c) ns
|
Sezik et al. [16] | a) 12 total hysterectomy + bilateral SLP b) 12 total hysterectomy without SLP |
n.r
|
-
|
n.r
| - | a) Basal 4.8 ± 1.4 1 month 4.2 ± 1.6 6 months 4.4 ± 2.1 b) Basal 5.9 ± 1.6 1 month 5.2 ± 1.6 6 months 5.5 ± 1.2 |
ns
|
Nakagawa et al. [17] | a) 6 SLP (HY) Type: not specified b) 11 PTD (HY) |
n.r
|
-
|
n.r
| - |
IU/L
Before surgery
a) 8.0 ± 2.9 b) 6.8 ± 1.1
After surgery
a) 8.6 ± 4.0 b) 14.1 ± 9.3 | a) ns
b) ns
|
Orvieto et al. [18] | a) 15 uni/bilateral SLP (HY) |
n.r
| - |
Before surgery
a) 5.6 ± 2.5 affected side 11.4 ± 4.5 both side
After surgery
a) 4.7 ± 2.3 affected side 9.5 ± 4.9 both side | a) .05
|
n.r
| - |
Xi et al. [20] | a) 76 SLP (ECP) - 44 unilateral - 32 bilateral b) 80 no surgery (healthy subjects) |
n.r
|
-
|
n.r
| - |
IU/L
Before surgery
a) 6.9 ± 1.5 7.5 ± 1.5 7.0 ± 1.5
After surgery
a) 7.2 ± 1.6 7.3 ± 1.2 7.2 ± 1.4 b) 7.2 ± 1.8 | a) ns
|
Na et al. [21] | a) 41 SLP (HY) Type: not specified b) 56 sclerotherapy (HY) |
n.r
|
-
|
n.r
| - |
IU/L
a) 8.2 ± 4.6 b) 10.9 ± 17.1 |
ns
|
Grynnerup et al. [25] | a) 16 SLP (HY) Type: not specified b) 42 no surgery (TF, with or without HY) c) 13 no surgery (unexplained infertility, no HY) |
pmol/L
a) 16,1 (5,2-54) b) 23,4 (3,5-50) c) 21.8 (12–64) | a) ns
b) ns
c) ns
|
n.r
|
-
|
n.r
|
-
|
Uyar et al. [23] | a) 33 patients (ECP) - 26 unilateral SLP - 3 salpingostomy b) 49 MTX (ECP) c) 80 no surgery | n.r |
-
| a) 10.1 ± 3.5 b) 10.3 ± 4.1 c) 10.1 ± 3.5 | a) ns
b) ns
c) ns
|
IU/L
a) 7.7 ± 3.8 b) 7.7 ± 2.3 c) 7.9 ± 1.9 | a) ns
b) ns
c) ns
|
Ni et al. [22] | 60 SLP (ECP, HY) a) 26 bilateral b) 34 unilateral c) 23 PTO (HY) d) 51 no surgery (TF, no HY) |
pg/mL
a) 90.00 b) 100.00 c) 100.00 d) 110.00 | a) ns
b) ns
c) ns
d) ns
| a) 9 b) 10 c) 11 d) 11 | a) ns
b) ns
c) ns
d) ns
|
IU/L
a) 7.35 ± 1.59 b) 7.17 ± 1.16 c) 7.64 ± 2.10 d) 7.13 ± 1.57 | a) ns
b) ns
c) ns
d) ns
|
Findley et al. [26] | a) 15 hysterectomy + bilateral SLP b) 15 hysterectomy with no SLP | a) Basal 2.26 ± 2.72 4–6 weeks 1.03 ± 1.04 3 months 1.86 ± 1.99 b) Basal 2.25 ± 2.57 4–6 weeks 1.25 ± 2.09 3 months 1.82 ± 3.12 |
ns
|
n.r
| - |
n.r
| - |
Hill et al. [27] | a) 36 SLP (ECP) Type: unilateral b) 153 MTX (ECP) |
n.r
| - | a) 10 (3–50) pre 10 (4–45) post b) 12 (1–53) pre 13 (1–60) post | a) ns
b) ns
|
IU/L
a) 7.2 (2.6 -16.0) pre 7.9 (5.1-10.4) post b) 6.9 (2.4-14.2) pre 7.2 (2.3-16.3) post | a) ns
b) ns
|
Pereira et al. [29] | a) 37 SLP (ECP) Type: unilateral b) 107 MTX (ECP) |
n.r
|
-
|
n.r
| - |
mIU/mL
a) 4.98 ± 2.19 pre 4.87 ± 2.97 post b) 4.81 ± 2.75 pre 4.94 ± 2.05 post | a) ns
b) ns
|
Ye et al. [28] | 124 SLP (HY, ECP, TOA) a) 83 unilateral b) 41 bilateral c) 74 no surgery (infertility, no TF) | fmol/mL a) 167,56 ± 127,03 b) 127,11 ± 93,23 c) 183.48 ± 104,37 |
.05
| a) 10,7 ± 3,62 b) 9,58 ± 3,73 c) 11,2 ± 4,16 |
ns
| mIU/mL a) 8.42 ± 2.3 b) 9.13 ± 3.2 c) 7.85 ± 2.69 |
.05
|
Venturella et al. [31] | a) 91 SLP standard b) 95 SLP wide Type: bilateral |
ng/mL
Before surgery
a) 0.93 ± 1.13 b) 0.86 ± 1.01
Δ After surgery
a) -0.09 ± 0.24 (Δ) b) -0.07 ± 0.22 (Δ) | a) ns
b) ns
|
Before surgery
a) 7.8 ± 4.23 b) 6.82 ± 4.68
Δ After surgery
a) -0.33 ± 0.73 (Δ) b) -0.26 ± 0.61 (Δ) | a) ns
b) ns
|
mIU/mL
Before surgery
a) 12.9 ± 9.71 b) 12.39 ± 7.88
After surgery
a) 0.47 ± 0.86 b) 0.37 ± 0.84 | a) ns
b) ns
|
IVF TREATMENT | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors & Years | Patients | E2 (on hCG day) ± SD |
p
| Stimulation Lenght (Days ± SD) |
p
| No. Oocytes retrieved ± SD/range |
p
| No. Obtained Embryos ± SD |
p
| No. transferred Embryos ± SD/range |
p
| Implantation Rate % (N) |
p
| Pregnancy Rate % (N) |
p
| Ongoing pregnancy rate % (N) |
p
|
Lass et al. [1] | a) 29 SLP (ECP) Type: unilateral b) 73 no surgery (healthy subjects) |
pmol/L
a) 6.087 ± 2.889 b) 6.635 ± 2735 |
ns
| a) 12.3 ± 1.6 b) 13.1 ± 2.0 |
ns
|
- General
a) 9.9 ± 5.3 b) 9.9 ± 5.3 c) Ipsilateral ovary 3.8 ± 3.0 Controlateral ovary 6.0 ± 3.6 | a, b) ns c) .01 |
n.r
| - | a) 2.4 ± 0.5 b) 2.0 ± 0.7 |
ns
|
n.r
| - | a) 17.2 (5) b) 13.7 (10) |
ns
|
n.r
|
-
|
Dechaud et al. [2] | a) 30 SLP (HY) Type: not specified b) 30 no surgery (TF, HY) |
pmol/L
a) 2.699 b) 1.903 |
ns
|
n.r
| - | a) 10.1 ± 5.0 b) 10.5 ± 6.0 |
ns
| a) 5.2 ± 3.4 b) 4.8 ± 3.7 |
ns
|
n.r
| - |
- First attempts
a) 10.4 (5/48) b) 4.6 (2/43)
- All attempts
a) 13.4 (21/156) b) 8.6 (10/116) |
ns
| - Per cycle
a) 23.7 (14/59) b) 16.3 (8/49)
- Per oocyte retrieval
a) 31.8 (14/44) b) 23.5 (8/34)
- Per transfer
a) 36.8 (14/38) b) 25 (8/32) |
ns
| a) 34.2 (13/38) b) 18.7 (6/32) |
ns
|
Bredkjaer et al. [3] | a) 139 SLP (HY) Type: 128 bilateral, 11 partial b) 139 no surgery (TF, no HY) |
n.r
|
-
|
n.r
|
-
| a) 9.3 b) 9.1 |
ns
|
n.r
|
-
| a) 2.1 b) 2.1 |
ns
| a) 19 b) 21 |
ns
| a) 40.3 (106) b) 40.5 (120) |
ns
| a) 21.7 (57) b) 21.6 (64) |
ns
|
Strandell et al. [4] | a) 116 SLP (HY) Type: not specified b) 88 no surgery (TF, HY) |
n.r
|
-
| a) 11.4 ± 2.2 b) 11.6 ± 2.9 |
ns
| a) 10.6 ± 5.9 b) 10.6 ± 6.1 |
ns
| a) 6.8 ± 4.8 b) 7.0 ± 4.9 |
ns
| a) 2.0 ± 0.3 b) 2.0 ± 0.4 |
ns
|
- Per transfer cycle
a) 22.8 (47/206) b) 18.8 (28/149)
- Ultrasound visible HY
a) 30 (21/70) b) 16.7 (13/78) |
ns
.05
| a) 36.6 (41) b) 23.9 (22) |
.05
| a) 28.6 (32) b) 16.3 (15) |
.05
|
Dar et al. [5] | a) 26 SLP (ECP) Type: 25 unilateral, 1 bilateral Control: same patients before surgery |
n.r
| - | Before surgery a) 10.81 ± 2.45 After Surgery a) 10.68 ± 2.57 |
ns
| Before surgery a) - Operated site
6.06 ± 3.85 - Non operated site
5.07 ± 3.08 After Surgery a) - Operated site
5.31 ± 4.22 - Non operated site 4.4 ± 3.68 |
ns
|
n.r
| - | Before surgery a) 3.56 ± 0.81 After Surgery a) 3.37 ± 0.8 |
ns
| After Surgery a) 23.07 | - | After Surgery a) 19.23 |
-
|
n.r
|
-
|
Strandell et al. [6] | Before surgery a) 26 SLP (general) b) 9 unilateral c) 17 bilateral After Surgery a) 26 SLP (general) b) 9 unilateral c) 17 bilateral |
n.r
|
-
| Before surgery a) 11 ± 2.4 b) 12.2 ± 2.4 c) 10.4 ± 2.3 After Surgery a) 11.2 ± 2.3 b) 12.2 ± 2.4 c) 10.6 ± 2.1 |
ns
| Before surgery a) 9.4 ± 5.9 b) 9.1 ± 4.4 c) 9.5 ± 6.7 After Surgery a) 8.7 ± 5.7 b) 7.7 ± 4.6 c) 9.2 ± 6.2 |
ns
| Before surgery a) 7.0 ± 5.6 b) 6.4 ± 3.9 c) 7.3 ± 6.5 After Surgery a) 5.9 ± 4.3 b) 5.3 ± 4.3 c) 6.2 ± 4.4 |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
Strandell et al. [7] | a) 103 SLP (HY) Type: 40 unilateral, 63 bilateral b) 82 no surgery (TF, HY) |
n.r
|
-
| a) 11.3 ± 2.1 b) 11.4 ± 2.6 |
ns
| a) 10.3 ± 5.4 b) 10.6 ± 5.4 |
ns
| a) 6.8 ± 4.1 b) 7.1 ± 4.4 |
ns
| a) 2.0 ± 0.3 b) 2.0 ± 0.3 |
ns
|
n.r
|
-
| ODD RATIO - Total group 1.7 - US visible HY 2.8 - US visible HY bilateral 6.9 |
.05
|
HAZARD R (BR)
- Total group 2.1 - US visible HY 3.8 US visible HY bilateral 6.0 |
.05
|
Surrey et al. [8] | a) 32 SLP (HY) Type: not specified b) 15 PTO (HY) c) 35 no surgery (TF no HY) d) 12 PTO (prior sterilization) | pg/mL a) 2.555 ± 219 b) 2.366 ± 282 c) 2.925 ± 259 d) 2.479 ± 281 |
ns
| a) 9.5 ± 0.2 b) 10.1 ± 0.4 c) 9.8 ± 0.2 d) 9.3 ± 0.3 |
ns
| a) 16.2 ± 1.2 b) 14.4 ± 1.8 c) 17.5 ± 1.8 d) 12.2 ± 1.3 |
ns
|
n.r
| a) 2.79 ± 0.2 b) 3.5 ± 0.4 c) 3.2 ± 0.2 d) 3.0 ± 0.3 |
ns
|
n.r
|
-
| a) 57.1 (16/28) b) 46.7 (7/15) c) 52.9 (18/34) d) 58.3 (7/12) |
ns
|
n.r
|
-
| |
Tal et al. [12] | a) 26 SLP (ECP) Type: unilateral b) 52 no surgery (healthy subjects) | pmol /L a) 5189 ± 3310 b) 5631 ± 3512 |
ns
| a) 11.6 ± 3.1 b) 10.8 ± 2.5 |
ns
| a) 8.6 ± 5.3 b) 8.4 ± 4.9 |
ns
| a) 5.5 ± 3.4 b) 4.0 ± 2.3 |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
Gelbaya et al. [10] | a) 40 SLP (HY) Type: 16 unilateral, 24 bilateral b) 25 PTD Type: 9 unilateral, 16 bilateral c) 103 no surgery (TF, no HY) |
pmol/L
a) 8558 ± 4337.98 b) 11192.7 ± 4167.3 c) 9512.78 ± 4173.9 |
.05
| a) 10.35 ± 1.92 b) 10.28 ± 1.02 c) 10.17 ± 1.37 |
ns
| a) 10.23 ± 6.08 b) 13.68 ± 5.17 c) 12.92 ± 8.75 |
.05
a vs b | a) 6.78 ± 4.58 b) 8.52 ± 4.75 c) 7.80 ± 5.48 |
ns
|
n.r
|
-
| a) 18.2 (10/55) b) 12.8 (5/39) c) 11 (18/163) |
ns
| a) 17.5 (7/40) b) 20 (5/25) c) 16.5 (17/103) |
ns
| a) 17.5 (7/40) b) 16.0 (4) c) 13.6 (14) |
ns
|
Moshin & Hotineanu [11] | a) 60 SLP (HY) b) 78 POT (HY) c) 66 no surgery (HY) type: not specified |
n.r
|
-
|
n.r
|
-
| a) 10.4 ± 6.0 b) 10.2 ± 5.7 c) 9.8 ± 5.5 |
ns
| a) 7.0 ± 4.7 b) 6.9 ± 4.6 c) 6.8 ± 4.6 |
ns
| a) 3.4 ± 1.2 b) 3.4 ± 1.3 c) 3.5 ± 1.3 |
ns
|
n.r
|
-
| a) 38 (23/60) b) 40 (31/78) c) 12 (8/66) |
.05
a,b vs c
|
n.r
|
-
|
Kontoravdis et al. [9] | a) 50 POT (HY) b) 50 SLP (HY) c) 15 no surgery (HY) type: not specified |
n.r.
|
-
| a) 12.3 ± 2.4 b) 11.9 ± 2.5 c) 13 ± 1.9 |
ns
| a) 11.6 ± 4.9 b) 12.1 ± 5.0 c) 10.9 ± 5.1 |
ns
| a) 8.7 ± 3.9 b) 8.53 ± 4.0 c) 7.9 ± 5.1 |
ns
| a) 2.6 ± 0.6 b) 2.6 ± 0.6 c) 2.6 ± 0.8 |
ns
| a) 19.5 b) 24.8 c) 5.6 |
.03 a vs c
.007 b vs c
| a) 44.4 b) 55.3 c) 14.3 |
.04
a vs c
.007 b vs c
| a) 37.8 b) 48.9 c) 7.1 |
.03
a vs c
.004 b vs c
|
Nakagawa et al. [17] | a) 11 PTD (HY) b) 6 SLP (HY) type: not specified |
pg/mL
a) 1553 ± 1468 b) 1530 ± 896 |
ns
|
n.r
|
-
| a) 5.3 ± 4.7 b) 7.5 ± 5.5 |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
| a) 45.5 b) 50.0 |
ns
|
n.r
|
-
|
Almog et al. [19] | Before surgery (HY, ECP) a) 36 SLP (22 unilateral, 14 bilateral) After Surgery a) 36 SLP |
pg/mL
Before surgery a) 1899.9 ± 185 After Surgery a) 1997 ± 231 |
ns
| Before surgery a) 10.5 ± 0.6 After Surgery a) 10.4 ± 0.4 |
ns
| Before surgery a) 10.2 ± 6.6 After Surgery a) 10.3 ± 7.4 |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
Orvieto et al. [18] | Before surgery (HY) a) 15 uni/bilateral After surgery b) 15 uni/bilateral |
pg/mL
a) 1,996 ± 885 b) 2,020 ± 981 | ns | b) 10.5 ± 1.7 a) 10.8 ± 1.5 | ns | a) 11.6 ± 5.9 b) 10.2 ± 6.1 | ns | n.r | - | a) 2.7 ± 1.1 b) 2.3 ± 0.7 | ns | a) 6.7 (1/15) b) 40 (6/15) |
.05
| n.r |
-
| ||
Xi et al. [20] | Before surgery (ECP) a) 76 SLP - 44 unilateral - 32 bilateral After Surgery a) 76 SLP - 44 unilateral - 32 bilateral b) 80 no surgery (healthy subjects) |
pg/mL
Before surgery a) 2663.5 ± 1246 2446.9 ± 983.8° 2512.5 ± 1119.4 After surgery a) 2783 ± 1281.3 2860.8 ± 1509.7 2585 ± 1216.2 b) 2934.8 ± 1234.9 |
ns
| Before surgery a) 10.7 ± 1.5 11.1 ± 1.5 10.7 ± 1.6 After surgery: a) 11.1 ± 1.8 11 ± 1.3 10.8 ± 1.9 b) 11.1 ± 1.8 |
ns
| Before surgery a) 11.1 ± 5.4 11.3 ± 5.1 11.9 ± 6.0 After surgery a) 11.6 ± 4.1 11.1 ± 4.3 11.9 ± 5.5 b) 11.5 ± 4.4 |
ns
| Before surgery a) 8.3 ± 4.4 7.5 ± 2.9 8.2 ± 4.3 After surgery a) 8.4 ± 3.9 8.4 ± 4.0 8.4 ± 3.4 b) 8.0 ± 3.1 |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
Na et al. [21] | a) 41 SLP b) 56 sclerotherapy type: not specified |
n.r
|
-
|
n.r
|
-
| a) 6.2 ± 1.0 b) 12.1 ± 11 |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
| a) 40 (17/43) b) 38 (23/60) |
ns
|
n.r
|
-
|
Lin et al. [24] | a) 103 SLP (HY, ECP) b) 185 (prior sterilization, tuboplasty, PTO) type: not specified |
pg/mL
a) 2153 ± 1239 b) 2340 ± 1529 |
ns
| a) 8.8 ± 1.4 b) 8.8 ± 1.5 |
ns
| a) 7.4 ± 3.9 b) 7.6 ± 4.1 |
ns
|
n.r
|
-
| a) 2.5 ± 0.8 b) 2.5 ± 0.8 |
ns
| a) 21.4 (56/261) b) 21.0 (98/465) |
ns
| a) 53.5 (55/99) b) 43.5 (77/177) |
ns
| a) 30.3 (30/99) b) 25.4 (45/77) |
ns
|
Ni et al. [22] | a) 26 bilateral SLP b) 34 unilateral SLP c) 23 PTO d) no surgery (TF, no HY) |
n.r
|
-
| a) 8.15 ± 1.29 b) 8.21 ± 1.27 c) 8.83 ± 1.37 d) 8.18 ± 1.35 |
ns
| a) 9.15 ± 3.73 b) 11.59 ± 6.14 c) 10.70 ± 4.92 d) 10.82 ± 4.82 |
ns
| a) 6.04 ± 2.85 b) 7.74 ± 4.23 c) 7.22 ± 3.25 d) 7.57 ± 3.74 |
ns
| a) 1.96 ± 0.45 b) 2.03 ± 0.39 c) 2.0 ± 0.43 d) 1.96 ± 0.20 |
ns
|
a) 51 (26/51)
b) 30.4 (21/69)
c) 39.1 (18/46)
d) 28 (28/100)
|
-
| a) 65.4 (17/26) b) 47.1 (16/34) c) 52.2 (12/23) d) 49 (25/51) |
ns
| LBR a) 61.5 (16/26 b) 41.2 (14/34) c) 52.2 (12/23) d) 45.1 (23/51) |
ns
|
Grynnerup et al. [25] | a) 16 SLP (HY) Type: (uni/bilateral) not specified b) 42 no surgery (TF, with or without HY) c) 13 no surgery (unexplained infertility, no HY) |
n.r
|
-
|
n.r
|
-
| a) 7 (3–31 range) b) 12 (3–30) c) 9 (9–38) |
.05
a vs b
|
n.r
|
-
| a) 2 (1–3) b) 2 (1–2) c) 2 (1–2) |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
Hill et al. [27] | Surgery Group (ECP) a) 36 unilateral SLP - pre-surgery - post-surgery Medical Group (ECP) b) 153 methotrexate - pre-treatment - post-treatment |
n.r
|
-
|
n.r
|
-
| a) - 13 (3–31) - 12 (3–31) b) - 14 (2–36) - 14 (0–35) |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
| a) 14 (39) b) 68 (44) |
ns
| a) 13 (33) b) 53 (35) |
ns
|
Pereira et al. [29] | a) 107MTX (ECP) → 88 IVF b) 37 unilateral SLP (ECP) → 22 IVF |
n.r
|
-
| a) MTX pre 9.55 ± 1.99 post 9.76 ± 2.33 b) SLP pre 9.63 ± 2.21 post 9.86 ± 1.93 |
a) ns
b) ns
| a) MTX pre 12.4 ± 5.77 post 10.6 ± 5.51 b) SLP pre 12.2 ± 6.43 post 10.2 ± 4.23 |
a) .03
b) ns
|
n.r
|
-
| a) MTX pre 2.92 ± 1.24 post 2.95 ± 1.38 b) SLP pre 2.86 ± 1.19 post 2.81 ± 1.01 |
a) ns
b) ns
|
n.r
|
-
|
n.r
|
-
| LBR a) MTX post 32.95 (29) b) SLP post 36.3 (8) | - |
Ye et al. [28] | a) 83 unilateral SLP b) 41 bilateral SLP c) 74 no surgery |
pg/mL
a) 38.3 ± 14.91 b) 41.41 ± 16.59 c) 36.49 ± 16.77 |
ns
| a) 9.6 ± 1.76 b) 9.39 ± 2.12 c) 9.78 ± 1.62 |
ns
| a) 7.83 ± 4.16 b) 6.98 ± 4.15 c) 8.42 ± 4.04 |
ns
| a) 3.39 ± 3.03 b) 3.15 ± 2.51 c) 3.5 ± 2.6 |
ns
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
n.r
|
-
|
Odesjo et al. [30] | a) 118 unilateral SLP b) 35 unilateral salpingotomy |
n.r
|
-
|
n.r
|
-
| a) 11.69 ± 5.59 b) 11.8 ± 6.1 |
ns
|
n.r
|
-
| a) 104 (88 %) b) 30 (85.7 %) |
ns
|
n.r
|
-
| a) 32 (27.1 %) b) 8 (22.9 %) |
ns
| LBR a) 21 (17.8) b) 7 (20) |
ns
|